Pirfenidone receives Priority Review

FDA accepted for filing and granted Priority Review to an NDA from InterMune Inc. (NASDAQ:ITMN) for pirfenidone to treat idiopathic pulmonary fibrosis. The PDUFA date is May 4. Pirfenidone is an oral ...